Assay Predicts Response to Neoadjuvant Atezolizumab Plus Chemotherapy in TNBC
The DetermaIO gene expression test was predictive of responses to neoadjuvant atezolizumab plus chemotherapy in early-stage triple-negative breast cancer.
The DetermaIO gene expression test was predictive of responses to neoadjuvant atezolizumab plus chemotherapy in early-stage triple-negative breast cancer.
As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.
CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Fixed-duration ibrutinib plus venetoclax generated meaningful survival benefits and durable responses in high-risk subgroups of patients with CLL/SLL.
An abstract is unavailable.
ASTCT introduces the Gene Therapy Summit, an interactive meeting of representatives from academic and clinical centers, the biotechnology industry, ASTCT and additional collaborative professional societies…
A single-dose formulation of paclitaxel for injectable suspension has been launched in the United States for metastatic breast cancer.
Redispensing unused oral cancer drugs can have a beneficial impact on climate change, ecosystems, and human health, a study suggests.
Joshua K. Sabari, MD, discusses the future treatment potential of tarlatamab as a combination therapy with other anticancer agents for previously treated SCLC, suggesting that…
Jacqueline Brown, MD, explains the need to determine optimal second-line bladder cancer treatments for use after enfortumab vedotin/pembrolizumab.